drugset / Trial / NCT06993974
Nitazoxanide in Patients With Ulcerative Colitis
Phase 2
Recruiting
70 enrolled
Alexandria University
Assoc. Prof. Dr. Ibrahim Fathi Amer, Faculty of Medecine, Kafr Elsheikh University. · collabAssoc. Prof. Dr. Noha Alaa Eldin Hassan Hamdy, Faculty of pharmacy, Alexandria University. · collabProf. Dr. Ahmed Ibrahim Mohammed El Mallah, faculty of pharmacy, Alexandria University. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Ulcerative colitis (UC) is a chronic inflammatory bowel Disease (IBD) that primarily affects the rectum and colon. The severity and persistence of mucosal inflammation are associated with morbidity and mortality.
Timeline
- Start
- 2025-05-30
- Primary completion
- 2026-08-20
- Completion
- 2026-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nitazoxanide | Other / unclassified | 500 mg | Oral |
| Comparator | Mesalamine | Small molecule | 1 g | — |